Accuray Q2 revenue falls 12%, swings to net loss

Accuray

04/02/2026 21:21

Overview

Radiation therapy firm's Q2 revenue fell 12% yr/yr

Company reported a net loss of $13.8 mln for Q2 compared to net income of $2.5 mln a year ago

Company initiated restructuring plan, incurring $6.1 mln in charges

Outlook

Accuray expects fiscal year 2026 revenue between $440 mln and $450 mln

Company projects adjusted EBITDA for fiscal year 2026 between $22 mln and $25 mln

Accuray anticipates $13 mln in restructuring charges for fiscal year 2026

Result Drivers

RESTRUCTURING PLAN - Accuray initiated a restructuring plan to reduce costs and streamline operations, incurring $6.1 mln in charges

PRODUCT REVENUE DECLINE - Product revenue decreased by 26% due to lower deliveries from China joint venture

SERVICE REVENUE INCREASE - Service revenue increased by 4% compared to the prior year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$102.24 mln
$100.85 mln (2 Analysts)
Q2 EPS
-$0.11
Q2 Net Income
-$13.77 mln
Q2 Basic EPS
-$0.11
Q2 Gross Profit
$24.07 mln
Q2 Income From Operations
-$11.57 mln
Q2 Operating Expenses
$35.64 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Accuray Inc is $3.88, about 415.5% above its February 3 closing price of $0.75

Press Release: ID:nPn8fb4sZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)